HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HUTCHMED (HCM) received China NMPA approval for SYVIK (sovleplenib) to treat adults with either of two autoimmune blood disorders. The approvals cover chronic primary immune thrombocytopenia after an insufficient response to at least one prior therapy and warm antibody autoimmune hemolytic anemia after an insufficient response to prior corticosteroid therapy. SYVIK is HUTCHMED’s first in-house immunology drug approved for commercialization.
In Phase III ESLIM-01, the durable platelet response rate was 48.4% with SYVIK versus 0% with placebo. In ESLIM-02, the durable response rate during weeks 5–24 was 66% versus 15% with placebo. The US FDA granted Orphan Drug Designation for primary immune thrombocytopenia and autoimmune hemolytic anemia in October 2026. HUTCHMED retains full worldwide rights to sovleplenib.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointChina approval for chronic primary immune thrombocytopenia covers adults with insufficient response to at least one prior therapy
- Major pointChina approval for warm antibody autoimmune hemolytic anemia covers adults with insufficient response to prior corticosteroid therapy
- Moderate pointESLIM-01 durable platelet response was 48.4% with SYVIK versus 0% with placebo in the 188-patient Phase III trial
- Moderate pointESLIM-02 durable response was 66% with SYVIK versus 15% with placebo during weeks 5–24
- Minor pointImmunology portfolio expansion marks HUTCHMED’s first commercialization approval for an in-house immunology drug
7 minor points
- Minor pointESLIM-01 overall response was 68.3% versus 14.5% through 12 weeks and 70.6% versus 16.1% through 24 weeks, SYVIK versus placebo
- Minor pointESLIM-02 overall response was 70% with SYVIK versus 22% with placebo during the 24-week double-blind treatment period
- Minor pointESLIM-02 safety showed no treatment-related deaths or discontinuations in the SYVIK group
- Minor pointESLIM-01 quality of life improved with SYVIK
- Minor pointESLIM-01 safety was described by HUTCHMED as tolerable
- Minor pointUS FDA Orphan Drug Designation was granted for primary immune thrombocytopenia and autoimmune hemolytic anemia in October 2026
- Minor pointWorldwide rights to sovleplenib remain entirely with HUTCHMED
Negative
- None.
Key Figures
- Simultaneous China approvals
- 2 NDAs
- SYVIK for ITP and wAIHA
- Durable response rate
- 48.4% vs 0% with placebo; p<0.0001
- ESLIM-01, primary ITP
- Overall response rate
- 68.3% vs 14.5% with placebo
- ESLIM-01, weeks 0–12
- Overall response rate
- 70.6% vs 16.1% with placebo
- ESLIM-01, weeks 0–24
- Durable response rate
- 66% vs 15% with placebo; p<0.0001
- ESLIM-02, weeks 5–24
- Overall response rate
- 70% vs 22% with placebo; p<0.0001
- ESLIM-02, 24-week double-blind treatment period
- Trial participants
- 188 adult patients
- ESLIM-01 in China
Historical Context
-
FDA granted designation for sovleplenib in primary ITP; the China application remained under review.
-
FDA granted designation for sovleplenib in autoimmune hemolytic anemia; the China applications remained under review.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
new drug applications (ndas) regulatory
placebo-controlled medical
orphan drug designation regulatory
spleen tyrosine kinase medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
— SYVIK® becomes the first novel Syk inhibitor approved in China —
— Simultaneous approvals in two underserved autoimmune indications supported by positive ESLIM-01 trial in ITP and ESLIM-02 trial in wAIHA —
— Expands HUTCHMED’s commercial portfolio into immunology, establishing a new presence beyond oncology —
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the China National Medical Products Administration (“NMPA”) has granted simultaneous approval for two New Drug Applications (NDAs) of SYVIK® (sovleplenib), a novel, selective oral small molecule inhibitor targeting spleen tyrosine kinase (“Syk”):
- Immune Thrombocytopenia (“ITP”): For the treatment of adult patients with chronic primary ITP who have had an insufficient response to at least one prior therapy; and
- Warm Antibody Autoimmune Hemolytic Anemia (“wAIHA”): For the treatment of adult patients with wAIHA who who have had an insufficient response to prior corticosteroid therapy.
The approval for ITP is supported by data from ESLIM-01 (NCT05029635), a randomized, double-blinded, placebo-controlled Phase III trial in China of SYVIK® in 188 adult patients who had received at least one prior line of standard therapy. Results from ESLIM-01 study were published in The Lancet Haematology. SYVIK® demonstrated a clinically meaningful early and sustained durable platelet response in patients with primary ITP compared to placebo, with durable response rate of
The approval for wAIHA is supported by data from ESLIM-02 (NCT05535933), a randomized, double-blind, placebo-controlled Phase II/III study in adult patients with primary or secondary wAIHA who had relapsed or were refractory to prior glucocorticoid treatment. Results from the Phase II part of ESLIM-02 were published in The Lancet Haematology. Results from the Phase III part were presented at the European Hematology Association (“EHA”) 2026 Congress. SYVIK® demonstrated a significantly higher durable response rate during weeks 5–24 compared to placebo (
Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: “The simultaneous approvals of SYVIK® for both ITP and wAIHA represent a significant milestone for HUTCHMED as our first in-house discovered immunology drug approved for commercialization. Patients with these chronic autoimmune blood conditions often face disease relapses and tolerability challenges associated with prolonged standard treatments. SYVIK® has demonstrated clinically meaningful efficacy, rapid onset, and sustained durable responses with a favorable safety profile across the pivotal ESLIM-01 and ESLIM-02 studies. We are committed to making this new targeted treatment option accessible to patients across China, addressing critical unmet needs and helping patients better manage these challenging conditions.”
In addition to the regulatory approvals in China, sovleplenib was granted Orphan Drug Designation by the US FDA for the treatment of primary ITP and autoimmune hemolytic anemia in October 2026. This designation underscores the clinical value of sovleplenib and its potential to address significant unmet medical needs on a global scale. HUTCHMED retains full worldwide rights to sovleplenib and continues to evaluate strategic pathways to support its global development.
About ITP
ITP is an autoimmune disorder characterized by immunologic destruction of platelets and decreased platelet production. Patients with ITP are at increased risk of excessive bleeding and bruising.1 ITP is also associated with fatigue (reported in up to
Adult ITP is a heterogeneous disease that can persist for years, even with best available care, and treatments are infrequently curative. Despite availability of several treatments with differing mechanisms of action, chronicity of disease continues to be a problem. Many patients develop resistance to treatment and thereby are prone to relapse.9 Thus, there remains a significant population of patients who have limited sensitivity to currently available agents and are in need of new treatments.
As platelet destruction in ITP is mediated by Syk-dependent phagocytosis of FcγR-bound platelets, Syk inhibition represents a promising approach to management of ITP.10
About wAIHA
Autoimmune hemolytic anemia (“AIHA”) is an autoimmune disorder characterized by the destruction of red blood cells (“RBCs”) due to the production of antibodies against RBC. The incidence of AIHA is estimated to be 0.8-3.0/100,000 adults per year with an estimated prevalence of 17 per 100,000 adults and a death rate of 8
The accelerated clearance of antibody-coated RBCs by immunoglobulin Fc-gamma receptor (FcγR) bearing macrophages is thought to be the pathogenic mechanism in wAIHA.15 Activated Syk mediates downstream signaling of the activated Fc receptors in phagocytic cells, resulting in phagocytosis of RBCs.16 In addition, activation of Syk through the B-cell receptor mediates activation and differentiation of B-lymphocytes into antibody secreting plasma cells.17 Inhibition of Syk may have potential effects in the treatment of wAIHA through inhibition of phagocytosis and reduction of antibody production.
About SYVIK®
SYVIK® (sovleplenib) is a novel, selective inhibitor of Syk. Syk is a major component in B-cell receptor and FcR signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.
HUTCHMED currently retains all rights to sovleplenib worldwide.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first five medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of sovleplenib, the further clinical development for sovleplenib, its expectations as to whether any studies on sovleplenib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of sovleplenib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in other jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of sovleplenib for a targeted indication; and HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for sovleplenib, and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Duncan Monteith / Ramin Naji | +44 20 7545 8000 |
_____________________________________________
REFERENCES
| 1 | Zufferey A, et al. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J. Clin. Med. 2017, 6(2), 16. |
| 2 | McMillan R, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008 Feb;83(2):150-4. |
| 3 | Snyder CF, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web‑based survey. Curr Med Res Opin. 2008 Oct;24(10):2767-76. |
| 4 | Doobaree IU, et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016 Oct;97(4):321-30. |
| 5 | Sarpatwari A, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010 Jul;95(7):1167-75. |
| 6 | Sarpatwari A, et al. Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). Br J Haematol. 2010 Oct;151(2):189-91. |
| 7 | Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835. |
| 8 | Clarivate Landscape & Forecast for Immune Thrombocytopenic Purpura, 2018. |
| 9 | Provan D, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. |
| 10 | Crowley MT, et al. A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages. J. Exp. Med. 186(7), 1027–1039 (1997). |
| 11 | Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007; 29 (1):1-9. doi: 10.1016/j.jaut.2007.05.002. |
| 12 | Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014; 89 (9):E150-5. doi: 10.1002/ajh.23767. |
| 13 | Cotran Ramzi S, Kumar Vinay, Fausto Nelson, Nelso Fausto, Robbins Stanley L, Abbas Abul K. Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders; 2005. p. 637. |
| 14 | Gehrs BC, Friedberg RC. Autoimmune haemolytic anemia. Am J Hematol. 2002; 69:258–271. doi: 10.1002/ajh.10062. |
| 15 | Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev. 2010; 24(3):195‐210. doi: 10.1016/j.tmrv.2010.03.002. |
| 16 | Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018; 14(10):857‐872. doi: 10.1080/1744666x.2018.1521722. |
| 17 | Davidzohn N, Biram A, Stoler‐Barak L, Grenov A, Dassa B, Shulman Z. SYK degradation restrains plasma cell formation and promotes zonal transitions in germinal centers. J Exp Med. 2020; 217(3):e20191043. doi: 10.1084/jem.20191043. |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.